Skip to main content
SpringerLink
Log in

Inhaled Glycopyrronium Bromide: A Review of its Use in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Inhaled glycopyrronium bromide (Seebri® Breezhaler® capsules; NVA237) is a once-daily, long-acting muscarinic receptor antagonist (LAMA) that is approved in several countries, including the EU, as a maintenance bronchodilator for the symptomatic treatment of adult patients with chronic obstructive pulmonary disease (COPD). In the randomized, controlled, phase III GLOW (GLycopyrronium bromide in chronic Obstructive pulmonary disease airWays clinical study)-1 and -2 trials, treatment with inhaled glycopyrronium bromide 50 μg once daily was associated with significantly better lung function than placebo in patients with moderate to severe COPD in terms of the trough forced expiratory volume in one second (FEV1) at 12 weeks (primary endpoint). Significant between-group differences in trough FEV1 in favour of inhaled glycopyrronium bromide were maintained for up to 52 weeks. Dyspnoea scores, health status and exacerbation rates were also improved to a greater extent in the inhaled glycopyrronium bromide than placebo groups in these trials. In the randomized, controlled, phase III GLOW3 trial, inhaled glycopyrronium bromide was associated with a significantly longer exercise endurance time than placebo after 3 weeks’ treatment in patients with moderate to severe COPD. The drug was generally well tolerated over the 26-week (GLOW1) or 52-week (GLOW2) study duration, and had a tolerability profile that was generally similar to that of tiotropium bromide. Serious adverse events were consistent with those expected in patients with moderate to severe COPD. In conclusion, inhaled glycopyrronium bromide is a once-daily LAMA that is an effective bronchodilator for use in the treatment of patients with moderate to severe COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed 8 Apr 2013.

  2. Hudd TR, Zaiken K. Management of chronic obstructive pulmonary disease: an emphasis on recently approved medications and products in the pipeline. Formulary. 2011;46(9):374–93.

    CAS  Google Scholar 

  3. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.

    Article  PubMed  Google Scholar 

  4. World Health Organization. World health statistics. 2008. http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. Accessed 8 Apr 2013.

  5. Novartis Europharm Ltd. Seebri® Breezhaler® (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf. Accessed 8 Apr 2013.

  6. Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;72(15):1999–2011.

    Article  PubMed  CAS  Google Scholar 

  7. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831–8.

    Article  PubMed  CAS  Google Scholar 

  8. Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328–34.

    Article  PubMed  Google Scholar 

  9. St Charles M, Blanchette CM, Silver H, et al. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin. 2010;26(10):2421–9.

    Article  Google Scholar 

  10. Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97–101.

    Article  Google Scholar 

  11. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371–84.

    PubMed  Google Scholar 

  12. Simoni-Wastila L, Wei Y-J, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother. 2012;10(3):201–10.

    Article  PubMed  Google Scholar 

  13. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–41.

    Article  PubMed  Google Scholar 

  14. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895–902.

    Article  PubMed  Google Scholar 

  15. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34(3):757–69.

    Article  PubMed  CAS  Google Scholar 

  16. Novartis Europharm Ltd. Oslif® Breezhaler® (indacaterol) powder for inhalation: EU summary of product characteristics. 2010. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001210/WC500053307.pdf. Accessed 8 Apr 2013.

  17. Boehringer Ingelheim Ltd. Spiriva® (tiotropium bromide monohydrate) powder for inhalation: UK summary of product characteristics. 2012. http://www.medicines.org.uk/EMC/medicine/10039/SPC/Spiriva+18+microgram+inhalation+powder%2c+hard+capsule/. Accessed 8 Apr 2013.

  18. Boehringer Ingelheim Ltd. Spiriva® Respimat® (tiotropium bromide monohydrate) solution for inhalation: UK summary of product characteristics. 2012. http://www.medicines.org.uk/EMC/medicine/20134/SPC/Spiriva+Respimat+2.5+micrograms+solution+for+inhalation/. Accessed 8 Apr 2013.

  19. AstraZeneca UK Ltd. Oxis® Turbohaler® 6 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http://www.medicines.org.uk/EMC/medicine/189/SPC/Oxis+Turbohaler+6%2c+inhalation+powder/. Accessed 8 Apr 2013.

  20. AstraZeneca UK Ltd. Oxis® Turbohaler® 12 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http://www.medicines.org.uk/EMC/medicine/190/SPC/Oxis+Turbohaler+12%2c+inhalation+powder/. Accessed 8 Apr 2013.

  21. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520–8.

    Article  PubMed  CAS  Google Scholar 

  22. Haddad E-B, Patel H, Keeling JE. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127:413–20.

    Article  PubMed  CAS  Google Scholar 

  23. Villetti G, Bergamaschi M, Bassani F, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148(3):291–8.

    Article  PubMed  CAS  Google Scholar 

  24. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660–8.

    Article  PubMed  CAS  Google Scholar 

  25. European Medicines Agency. Seebri® Breezhaler® (glycopyrronium bromide): European Medicines Agency assessment report. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf. Accessed 8 Apr 2013.

  26. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673–8.

    Article  PubMed  CAS  Google Scholar 

  27. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729–41.

    Article  PubMed  CAS  Google Scholar 

  28. Verkindre C, Fukuchi Y, Flémale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104(10):1482–9.

    Article  PubMed  CAS  Google Scholar 

  29. Sechaud R, Renard D, Zhang-Auberson L, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118–28.

    PubMed  CAS  Google Scholar 

  30. D’Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.

    Article  PubMed  Google Scholar 

  31. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–14.

    Article  PubMed  CAS  Google Scholar 

  32. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–13.

    Article  PubMed  CAS  Google Scholar 

  33. Fogarty C, Hattersley H, Di Scala L, et al. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011;105(3):337–42.

    Article  PubMed  Google Scholar 

  34. Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012;12:74.

    Article  PubMed  Google Scholar 

  35. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23(5):438–44.

    Article  PubMed  CAS  Google Scholar 

  36. Novartis Pharmaceuticals Canada Inc. Seebri® Breezhaler® (glycopyrronium bromide) powder for inhalation: Canadian prescribing information. 2012.

  37. Novartis. Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1645116.shtml. Accessed 8 Apr 2013.

  38. Novartis. Novartis QVA149 phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1637183.shtml. Accessed 8 Apr 2013.

  39. Novartis. Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1638207.shtml. Accessed 8 Apr 2013.

  40. Novartis. Novartis QVA149 phase III COPD studies meet primary endpoints. 2012. http://www.novartis.com/newsroom/media-releases/en/2012/1599186.shtml. Accessed 8 Apr 2013.

  41. The Pharma Letter. Novartis/Vectura’s QVA149 is filed as a treatment for COPD in Europe. 2012. http://www.thepharmaletter.com/file/117552/novartisvecturas-qva149-is-filed-as-a-treatment-for-copd-in-europe-certican-eu-approval.html. Accessed 8 Apr 2013.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Natalie J. Carter

Authors
  1. Natalie J. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalie J. Carter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, N.J. Inhaled Glycopyrronium Bromide: A Review of its Use in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease. Drugs 73, 741–753 (2013). https://doi.org/10.1007/s40265-013-0058-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0058-7

Keywords

Search

Navigation